cytic syndrome (HPS) and TMA. In particular, VOD and TMA are involved in abnormalities of the haemostasis and coagulation system.
Injury to sinusoidal endothelial cells and hepatocytes by chemotherapy appears to be the primary event in the pathogenesis of VOD (6, 7) . A number of markers for endothelial injury and adhesion molecules are upregulated in patients with VOD, including plasma thrombomodulin (TM), E-selectin, tissue factor, tissue factor pathway inhibitor and plasminogen activator inhibitor (8) . Consequently, some biomarkers of endothelial injury are essential for predicting the development of VOD (9) . On the other hand, heparin is often used for the prevention of VOD, since it is an anticoagulant therapy (10) . However, in a previous report by the authors, elevation of soluble (s) E-selectin and sVCAM-1 was observed despite heparin administration to prevent VOD after HSCT (11) . Therefore, heparin may be inadequate for the prevention of VOD. In the present study, we measured sE-selectin and sVCAM-1 after HSCT using recombinant (r) TM (12, 13) instead of heparin. In addition, tumour necrosis factor (TNF)-α, high mobility group box 1 (HMGB1) and interleukin (IL)-6 were measured. To the best of our knowledge, no other investigators have measured these markers before and after rTM treatment in patients with allogeneic HSCT.
This study involved 12 patients (4 acute myeloid leukemia, 3 myelodysplastic leukaemia, 2 adult T-cell leukemia and 3 others) who underwent HSCT at the institution of residence, all of whom received allogeneic HSCT. The sources of donor tissue were three bone marrow transplantations, four peripheral blood HSCTs and five cord blood transplantations. RTM, consisting of daily doses of 380 units/kg (Asahi Kasei Pharma, Tokyo, Japan) was administered as a preventive therapy for VOD. This protocol was completed 7-21 days after HSCT. An anticoagulation regimen (5,000 U heparin 24 hours/day) was used prior rTM. Heparin was also administered to the Control group. Prior approval was obtained from the ethics review boards of all the participating institutions. Written informed consent was also obtained from all patients prior to rTM therapy.
As shown in ǠTable 1, all the cytokines and soluble factors exhibited significant elevations on day 0 after HSCT. In addition, IL-6 and TNF-α exhibited more significant elevations on days 4-7 after HSCT (before rTM treatment). However, the levels of HMGB1, sE-selectin and sVCAM-1 did not exhibit significant changes on days 4-7. Significant improvements in IL-6, TNF-α and HMGB1 levels were noted after rTM treatment, but not after heparin treatment. In contrast, the levels of sE-selectin and sVCAM-1 did not show significant changes after rTM treatment. However, heparin treatment resulted in a significant increase in these soluble factors.
Our results suggest that rTM treatment after allogeneic HSCT may prevent VOD. Several approaches have been evaluated for the treatment of VOD, but none has been uniformly effective (14) . One of the most promising agents as a therapy for VOD is defibrotide, a novel polydeoxyribonucleotide with adenosine receptor agonist activity (15) . The results from a multi-institutional study have confirmed the benefits of this agent in therapy for established VOD (16) . However, one of the action mechanisms of this agent depends on increased of TM on the endothelial surface (17, 18) . Indeed, it has recently been reported that rTM is effective for certain complications after allogeneic HSCT (19, 20) . In these cases, rTM exhibited a suppressive effect on the weight gain that is characteristic of VOD, suggesting an inhibitory effect of rTM on capillary vessel leakage (19, 20) . On the other hand, useful examinations are essential for the achievement of preventive therapy for VOD. It has recently been reported that certain biomarkers of endothelial injury are useful for the prediction of VOD after allogeneic HSCT (9) . In particu- Data represent the means ± standard error. IL-6: interleukin 6; TNF-α: tumour necrosis factor-α; HMGB1: high mobility group box protein 1; sVCAM-1: soluble vascular cell adhesion molecule-1; sE-selectin: soluble E-selectin. Statistical analysis exhibit "Before HSCT" vs. "After HSCT(day 0)": †õ p < 0.001; ‡ö p < 0.01; "Before rTM" vs. "After rTM": * p < 0.01; ** p < 0.05; NS: not significant.
HMGB1 (IU/ml) 5.1 ± 1.2 23.6 ± 9.9 ‡ 24.5 ± 6.7 23.7 ± 6.2 NS lar, TM, sE-selectin and sVCAM-1 appear to be convenient markers for the prediction of VOD (9) . The absence of effective therapies for VOD has spurred much interest in developing effective preventive strategies for the disease (14) . For this reason, heparin has previously been the best-studied agent used for prevention (10) . However, in the present study, increased level of sE-selectin and sVCAM-1 was observed despite heparin administration after HSCT. In contrast, the levels of sE-selectin and sVCAM-1 did not show significant changes after rTM treatment. We were unable to document VOD in the patients before rTM treatment in this study. Therefore, we do not have any direct evidence to suggest that rTM actually prevented VOD. In addition, the decrease in sE-selectin and sVCAM-1 levels do not necessarily suggest a preventive effect for rTM. However, we recently observed high levels of sE-selectin and sVCAM-1 in a patient with VOD (unpublished data). The aetiology of VOD remains unclear; although we believe one of the causes of VOD to be pro-inflammatory cytokines, such as HMGB1 (21, 22) . For this reason, it is thought that the direct anti-inflammatory effect mediated via the rTM lectin domain plays an important role in preventing VOD. The present findings suggest the possibility that rTM can play a preventive role for VOD after allogeneic HSCT. However, there are still many unclear points regarding the therapeutic effects of rTM shown in "SIGHT", including the action mechanism.
Further studies using more patients and a revised protocol are required to further elucidate the mechanism by which rTM prevents VOD.
